| Title |
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, October 2015
|
| DOI | 10.2147/tcrm.s88208 |
| Pubmed ID | |
| Authors |
Giorgio Lorenzo Colombo, Calogero Cammà, Adolfo Francesco Attili, Roberto Ganga, Giovanni Battista Gaeta, Giuseppina Brancaccio, Jean Marie Franzini, Marco Volpe, Giuseppe Turchetti |
| Abstract |
Hepatocellular carcinoma (HCC) is a severe health condition associated with high hospitalizations and mortality rates, which also imposes a relevant economic burden. The aim of the present survey is to investigate treatment strategies and related costs for HCC in the intermediate and advanced stages of the disease. The survey was conducted in four Italian centers through structured interviews with physicians. Information regarding the stage of disease, treatments performed, and related health care resource consumption was included in the questionnaire. Direct health care cost per patient associated with the most relevant treatments such as sorafenib, transarterial chemoembolization (TACE), and transarterial radioembolization (TARE) was evaluated. Between 2013 and 2014, 285 patients with HCC were treated in the four participating centers; of these, 80 were in intermediate stage HCC (Barcelona Clinic Liver Cancer Classification [BCLC] B), and 57 were in the advanced stage of the disease (BCLC C). In intermediate stage HCC, the most frequent first-line treatment was TACE (63%) followed by sorafenib (15%), radiofrequency ablation (14%), and TARE (1.3%). In the advanced stage of HCC, the most frequently used first-line therapy was sorafenib (56%), followed by best supportive care (21%), TACE (18%), and TARE (3.5%). The total costs of treatment per patient amounted to €12,214.54 with sorafenib, €13,418.49 with TACE, and €26,106.08 with TARE. Both in the intermediate and in the advanced stage of the disease, variability in treatment patterns among centers was observed. The present analysis raises for the first time the awareness of the overall costs incurred by the Italian National Healthcare System for different treatments used in intermediate and advanced HCC. Further investigations would be important to better understand the effective health care resource usage. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 75% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 5% |
| Netherlands | 1 | 2% |
| Unknown | 39 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 24% |
| Other | 8 | 19% |
| Researcher | 7 | 17% |
| Professor | 2 | 5% |
| Student > Bachelor | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 13 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 45% |
| Agricultural and Biological Sciences | 2 | 5% |
| Immunology and Microbiology | 2 | 5% |
| Business, Management and Accounting | 1 | 2% |
| Nursing and Health Professions | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 14 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2017.
All research outputs
#6,753,656
of 25,371,288 outputs
Outputs from Therapeutics and Clinical Risk Management
#325
of 1,323 outputs
Outputs of similar age
#75,023
of 286,873 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#12
of 53 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,873 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.